Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Wisconsin, Madison
About this trial
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
Eligibility criteria
Qualifiers
Willing to provide informed consent.
Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
Individuals at least 18 years of age.
Disqualifiers
Not able to receive treatment with ICI therapy
Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
Women who are pregnant, lactating, or planning on becoming pregnant during the study.
Not suitable for study participation due to other reasons at the discretion of the investigators.
Trial design
Treatments tested in this trial
- 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov